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Abstract
Background: Solitary fibrous tumours (SFT) are neoplasms of mesenchymal origin that predominantly arise from
the pleura. SFT of the liver (SFTL) are a rare occurrence with little number of cases reported in English literature.
Malignant cases of hepatic SFT are an even rarer occurrence. For this reason, the prognostic evaluation of SFTLs is
unknown and difficult to measure.
Methods: A search on English literature on “Solitary Fibrous Tumour of the Liver” was conducted on common
search engines (PubMed, Google). All published articles, case reports and literature reviews and their reference lists
were reviewed.
Case report: This paper presents a 61-year-old male who was referred to a tertiary hospital in April 2010 with
marked hepatomegaly. USS, CT and MRI scans were suggestive of a neoplasm, and the patient underwent a
subsegmental IVb resection in June 2010. The specimen demonstrated histological and immunohistochemical
features of malignant SFTL with clear resection margins. The patient was followed up regularly for 3 years with
imaging and no suggestion of recurrence. Six years after the initial surgery, the patient represented with worsening
right upper quadrant pain and dyspnoea secondary to extensive tumour recurrence adjacent to the resection site
and metastatic deposits in the pleura. The patient was managed symptomatically and discharged for community
follow-up after palliative involvement.
Conclusions: SFTL are rare with only 84 cases reported in the English Literature including the present case. The
average age of patients is 57.1 and occurs in females more than males (1.4:1). Most SFTLs follow a benign course,
however, 17.9% of cases displayed malignant histological features. Only three cases including the current case are
reported to have both local recurrence and metastasis. Surgical resection remains the mainstay of treatment and
appears to be curative of most cases. The rarity of this tumour makes it difficult to evaluate its prognosis and
natural course.
Keywords: Solitary fibrous tumour of the liver, Hepatic tumours, Mesenchymal neoplasms, Malignancy, Metastasis,
Hepatobiliary
Background
Solitary fibrous tumours (SFT) are soft tissue neoplasms
of mesenchymal origin first described in 1931 by
Klemperer and Rabin [1]. They are typically found in the
pleura but are ubiquitously distributed and have been
reported to originate from a number of extrapleural sites.
Solitary fibrous tumours of the liver (SFTL) are rare, with
only 84 reported cases in the English literature (PubMed
+Google + publication references) including the present
case. Most SFTLs are benign but there have been a hand-
ful of reports on malignant cases, some of which have had
local recurrences and metastatic spread.
Diagnosis is typically made with histopathological find-
ings and immunohistochemical examination of resected
samples. Preoperative investigation of SFTLs can be
difficult with non-specific radiological features. Biopsy of
radiological liver lesions remains controversial due to
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the risk of inconclusive results [2, 3] or seeding of the
biopsy tract [4]. Given the malignant potential of these
tumours, surgical resection is the preferred method of
treatment if possible.
This report is only the third described case of its kind
in the English literature, a malignant SFTL with exten-
sive local recurrence and metastatic spread 6 years
following clear resection margins.
Main text
Case presentation
A 61-year-old male was referred to the emergency
department by his general practitioner in April 2010 for
investigation of loose bowel motions and an episode of
black stool. The patient had a history of insulin-
dependent type II diabetes mellitus, hypertension,
ischaemic heart disease with two previous ischaemic
events, obstructive sleep apnoea, depression, schizophre-
nia and a previous incisional hernia repair.
On examination, he was morbidly obese (BMI 45) and
was noted to have marked hepatomegaly. This was not
associated with any recent weight loss, haematemesis,
jaundice or abdominal pain. The patient denied previous
blood transfusions, usage of intravenous drugs and did
not drink alcohol. A faecal occult blood test was
negative, and the patient’s last colonoscopy 2 years prior
was unremarkable.
He was referred to our tertiary centre for further man-
agement after an ultrasound scan (USS) displayed an
ovoid mass of mixed echogenicity arising from the liver,
measuring 12 × 9 cm. A computed tomography (CT)
scan confirmed a malignant appearing, pedunculated
lesion attached to segment IV (Fig. 1). A subsequent
magnetic resonance imaging (MRI) confirmed that on
T2 weighted imaging (WI), the lesion was isointense to
the liver peripherally with central branching hyperinten-
sities (Fig. 2a) which corresponded to the hypointensities
seen on T1WI (Fig. 2b). Enhancement of the lesion was
noted in arterial phase (Fig. 3a), during portal venous
phase (Fig. 3b) and at 2 min (Fig. 3c), with some central
areas of non-enhancement. The lesion becomes slightly
hypointense on delayed images at 10 (Fig. 3d) and
20 min compared to the surrounding liver.
Laboratory investigations revealed a mildly elevated
gamma-glutamyl transpeptidase of 137 IU/L (normal 5–
50 IU/L). Hepatitis screen, alpha-fetoprotein, carcinoem-
bryonic antigen and cancer antigen 19–9 were all
unremarkable.
The patient underwent a subsegmental resection of
the 15 cm segment IVb mass in June 2010. There was
severe hepatic steatosis, but no cirrhosis. The patient
was discharged postoperative day seven without
complications.
Pathology of the resection specimen confirmed SFTL.
The specimen displayed a pale tan nodular appearance
with a firm and rubbery cut surface. Histological exam-
ination revealed fascicles of spindle cells in storiform ar-
rangement with a pushing margin. There was evidence
of extracellular collagen deposition, areas of myxoid
stroma and branching vessels with hyalinisation. The
specimen displayed a high mitotic rate of up to 9 per 10
high-power fields (HPF) with no necrotic or haemor-
rhagic features. Immunohistochemistry showed positive
staining for CD34, CD99 and BCL-2. The tumour was
negative for c-Kit, CD31, SMA, desmin, cytokeratins
(AE1/AE3, MNF116 and Cam 5.2), EMA and S100. The
margins were clear. The non-neoplastic remainder of
the liver displayed pericellular fibrosis indicative of
steatohepatitis.
The patient was followed-up regularly every 4 to
6 months with CT scans by the local general practitioner
who liaised with the consultant surgeon. There were two
episodes of re-admissions for further investigation of re-
current right upper quadrant pain between 2011 and
2013. Multiple MRI scans performed during this period
revealed expected postsurgical changes with no tumour
recurrence. However, in May 2016, the patient presented
to his local emergency department with progressively
worsening right upper quadrant pain and increasing dys-
pnoea with an oxygen demand. CT of his chest,
abdomen and pelvis revealed extensive tumour recur-
rence adjacent to the previous resection site (Fig. 4). In
addition, there was a clinically significant right-sided
pleural effusion and a pleural mass at the right lung base
measuring 3.8 cm (Fig. 5).
Pleurocentesis was performed, draining 1400 ml of
serosanguineous fluid. Cytology was negative for malig-
nant cells. The case was discussed extensively in a multi-
disciplinary setting, and it was decided given the
patient’s two sites of disease and significant perioperative
risk that he was not a candidate for radical reoperation.
Fig. 1 Abdominal CT displaying the pedunculated liver lesion arising
from segment IV
Chen and Slater World Journal of Surgical Oncology  (2017) 15:27 Page 2 of 12
There were also no suitable chemo- or radiotherapeutic
therapies available. The patient was subsequently re-
ferred to the palliative team for management of his
symptoms and discharged back to the community. He
was still alive 1 month after discharge.
Discussion
SFTs are fibroblastic neoplasms first described in 1931
[1] that are of mesenchymal origin and typically arise
from the pleura. Initially thought to be of mesothelial
origin, they have been historically referred to as benign
mesothelioma, localised fibrous mesothelioma and
pleural fibromas [5]. Their extrapleural involvement and
ubiquitous nature have been well described over the last
century with publications documenting primary cases
arising from the respiratory tract [6], orbit [7], thyroid
[8], adrenal gland [9], spinal cord [10], meninges [11],
breasts [12], peritoneum [13], pancreas [14] and soft
tissues [15].
SFTs involving the liver are exceptionally rare with
only 84 cases reported in the English literature since
1958 (Table 1). The average age of patients is 57.1 (range
16–87) and appears to occur in females more than males
(1.4:1). Most SFTLs follow a benign course, however,
17.9% (n = 15) of cases displayed malignant histological
features.
The clinical presentation of SFTL is generally non-
specific, ranging from weight loss and fatigue to upper
abdominal fullness [16] or discomfort due to the ten-
dency of these tumours to be quite large. In many cases,
SFTLs are found incidentally during routine examination
[17–22] or on routine imaging while investigating other
pathologies [2, 23–25]. Patients may also present with
symptoms secondary to compression of visceral or
neurovascular structures adjacent to the mass such as
Fig. 2 Abdominal MRI displaying the liver lesion. a T2WI. b T1WI
Fig. 3 MRI T1WI after contrast. a Arterial phase. b Portal venous phase. c Delayed 2 min. d Delayed 10 min
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dyspepsia [26], postprandial pain/nausea/vomiting [22,
27–29] or jaundice [30]. There is no specific laboratory
or tumour marker for SFTL, and serum investigations
are generally non-informative. A small percentage of
patients (13.1%) however, present with paraneoplastic
syndromes such as non-islet cell tumour hypoglycaemia
[31] associated with extrinsic production of high-
molecular weight insulin-like growth factor II (IGF-II)
which spontaneously resolves after resection of the mass
[17, 19, 24, 30–37]. There does not appear to be an asso-
ciation between hypoglycaemic presentations and malig-
nant cases (n = 1). These IGF-II associated SFTs have
also been documented in cases involving the pleura and
so are not limited to SFTLs [38].
Preoperative diagnosis is difficult due to non-specific
radiological findings. Sonography often reveals a hetero-
geneous mass which may be either or both hypo- and
hyperechogenic with or without calcifications. A
contrast-enhanced CT characteristically shows early ar-
terial enhancement with delayed venous washout [3, 22].
Findings on MRI are similar to that of CT scans. In
T1WI, the SFTL demonstrates a heterogeneous mass
with hypointense signals compared to the normal hep-
atic parenchyma which is thought to reflect the high
content of collagenous tissue [39, 40]. A heterogeneous
mass that may be both hypo- and hyperintense is ob-
served in T2WI with some areas described as almost
isointense to cerebrospinal fluid [18, 41]. On images
post-gadolinium-based contrast injection, SFTLs display
progressive heterogeneous enhancement starting in the
arterial phase corresponding to the hypervascular areas
and persisting into the venous and delayed phases, likely
Fig. 4 CT abdomen of recurrent disease adjacent to resection site. a–b Axial views. c–d Transverse views
Fig. 5 CT chest transverse view displaying right-sided pleural mass
associated with significant unilateral pleural effusion
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due to the collagen-rich interstitium [42]. There does
not appear to be any features on either USS, CT or MRI
that differentiates between benign or malignant disease
without a tissue diagnosis.
Percutaneous biopsy for tissue diagnosis prior to re-
section is a much debated topic but is a well-
documented approach in the lead up to the resection of
SFTLs [3, 16, 18, 27, 28, 31, 40, 43–47]. Given the many
risks it poses—including seeding the tumour via the nee-
dle tract [4, 48], pain, intrahepatic or subcapsular
haematoma and bile leaks [4]—it is doubtful whether
preoperative biopsy would change management if the le-
sion is able to be safely resected [24]. Fuksbrumer et al.
[18] describes a case which showed histological changes
suggesting low-grade malignant transformation which
was not discovered in the initial biopsy while Korkolis et
al. [3] reports a case of SFTL whose initial biopsy was
indicative of hepatocellular carcinoma. A third report by
Chen et al. [2] presents a case in which a biopsy sug-
gested metastatic pancreatic or upper gastrointestinal
tract lesion in a patient with a history of colorectal
adenocarcinoma prior to resection. Postoperative histo-
logical examination indicated SFTL and disproved the
preoperative diagnosis.
Diagnosis is limited to histopathological and immuno-
histochemical investigations. Macroscopic examination
of SFTLs appears to be relatively consistent amongst all
cases in this literature review. SFTLs range in size,
measuring from 0.5 [17] to 35 cm [34]. They tend to be
grey-white or tan-yellow in colour and are well-
circumscribed, nodular and encapsulated by a smooth
glistening capsule, often continuous with the Glisson’s
capsule [27, 47, 49]. On the cut surfaces, they are well
documented to be firm and difficult to cut with a
whorled bulging appearance interspersed with central
areas of scarring and radiating bands of fibrous tissue.
Some SFTLs may also display features of myxoid degen-
eration [3, 22, 26, 40, 50], necrosis [20, 27, 28, 35, 42, 51,
52], haemorrhage [20, 51] or cystic cavitation [2, 24, 29,
34, 35, 40, 42, 53].
Microscopically, they are composed of ovoid spindle-
shaped cells with little cytoplasm within a characteristic
storiform or haphazardly ‘pattern-less pattern’ architec-
ture. These cells are distributed between alternating
hypo- and hypercellular areas separated from each other
by thick bands of keloid-like collagen bundles and
branching of staghorn vessels resembling a
haemangiopericytoma-like pattern. Myxoid changes
were also commonly observed [17, 26]. Mitoses are rare
and generally limited to malignant cases, as is necrosis
and cytological atypia. Most cases displayed mitoses <4/
10HPF. In 2002, the World Health Organization (WHO)
revised their classification of tumours and recognised
SFTs as a fibroblastic/myofibroblastic tumour and
identified it as a separate entity to haemangiopericyto-
mas. Features identified by WHO to be associated with
malignancy include hypercellularity, cytologic atypia,
tumour necrosis, infiltrative margins and high mitotic
activity (≥4/10 HPF) [54].
There are no specific immunohistochemical profiles
for SFTL, however, there are a few markers which are
characteristic such as CD34 which has shown strong re-
activity in all documented cases as well as CD99, BCL-2
and Vimentin which do not appear as sensitive. Durak et
al. [55] reports an interesting case in which there was a
strong positivity for CD34 and CD99 but similarly for
smooth muscle actin and focal weak positivity for
oestrogen and progesterone receptors in the spindle cells
which has not been documented before. Few cases re-
port immunoreactivity to desmin [3, 51] (n = 2) and
actin [51, 55] (n = 2). SFTLs are otherwise typically nega-
tive for c-Kit (CD117), CD31, cytokeratins, EMA, factor
VIII, epithelial membrane antigen and S100.
On literature review, there appears to be sixteen cases
documenting malignant SFTLs (Table 2), local recur-
rence or distant metastases. 17.9% (n = 15) of patients
were diagnosed with malignant SFTL based on the hist-
ology reports. The average age of these patients was
59.6 years with almost equal distribution between males
and females (7:8). Of these cases, 26.7% (n = 4) were
noted to have local recurrence (9 months–6 years) and
53% (n = 8) to have distant metastasis (1 month–6 years).
This compared similarly to intrapleural SFTs with recur-
rence rates of 20–67% in malignant tumours [35].
Only three cases [35, 51] including the current case
are reported to have both local recurrence and metasta-
sis but no significant features to foresee this could be
identified in this data. All three were male and their
average age was 61.7 years. The size of tumours ranged
from 11 to 27 cm and two of the three cases had high
rates of mitoses (>9/10 HPF). It is interesting to note
that Du et al. [56] reports a case on a 55-year-old female
with non-malignant SFTL who represented 5 years after
initial surgery with local recurrence and associated
hypoglycaemia which resolved spontaneously after resec-
tion. The tumour did not display any marked variances
when compared to other non-malignant SFTLs.
Surgical resection remains the mainstay of treatment
for SFTLs and appears to be the cure for most cases
where histopathology returns showing a benign lesion
with a clear resection margin of >1 cm. There is very lit-
tle literature on the use of radio- and chemotherapy, and
its efficacy in the long-term is unknown given the scant
experience with these approaches. El-Khouli et al. [43]
describes a case of SFTL treated with three sessions of
transarterial chemoembolisation (TACE) for an inoper-
able lesion. They describe a favourable outcome on the
basis of increased intratumoral necrosis, reduced
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tumoural enhancement and stabilisation of tumour size
based on consecutive MRI scans. Beyer et al. [45]
describes a case where the SFTL was initially thought to
be a desmoid tumour, and the patient was managed with
hormone replacement therapy before imatinib was
trialled with no effect. The patient eventually underwent
surgical resection with no malignant features evident.
Feng et al. [20] presents a case series with one patient
undergoing adjuvant chemotherapy (mitomycin) due to
extensive tumour infiltration of multiple vascular struc-
tures and another patient who was trialled on percutan-
eous microwave coagulation therapy and percutaneous
ethanol injection for local recurrence without success as
new lesions were found 6 months later on follow-up.
Maccio et al. [46] reports a case series where two
patients underwent chemotherapy for SFTL with meta-
static spread to the lungs without success as both
patients died within 5 months.
Prognosis for SFTLs is unknown and difficult to meas-
ure due to the little experience and understanding of the
biological nature of the disease. The rarity of this
tumour makes it hard to gather enough cases for a study
on alternative treatment options, and the absence of
long-term follow-up also hinders on the evaluation of
patient outcome over long-periods for both benign and
malignant cases. The use of adjuvant radio- and/or
chemotherapy as well as TACE is scarcely reported and
so its efficacy cannot be commented on. It would be
valuable to review these patients several years down the
track to see how their disease has progressed.
Conclusion
SFTL is a rare neoplasm that should be considered in
the differential diagnosis of patients presenting with
vague abdominal symptoms secondary to compression
of adjacent structures due to a large hepatic mass.
Radiological findings are often non-specific and are un-
able to differentiate between a benign or malignant mass
and percutaneous biopsies are not recommended if the
tumour is considered resectable. Complete surgical re-
section is, thus, the recommended treatment of choice
and curative in most cases as the risk for malignant
transformation and metastatic spread is not unheard of.
Careful long-term follow-up is suggested as prognosis is
uncertain for these lesions. This case provides yet an-
other example of the malignant potential of SFTLs to
recur locally and metastasise to distant locations.
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